Eos Biosciences Inc. is a privately held Los Angeles-based Nanomedicines company founded in 2013. The Company has secured an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed by Dr. Lali Medina-Kauwe at Cedars-Sinai Medical Center (Los Angeles).  The technology is based on generating self-assembling, nanobiologic particles (Eosomes) that entrap and encapsulate a chosen therapeutic and specifically deliver it to the interior of the target disease cell. Such specific targeting allows for improved efficacy and safety profiles of the therapeutic payload.